Metrics as of 10/15/2026, 05:51 AM (Berlin time), refresh in progress.
Atea Pharmaceuticals Stock
Atea Pharmaceuticals, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Jean-Pierre Sommadossi
- Employees
- 55
- Market cap
- $346 M
- IPO
- 30/10/2020
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in…
Atea Pharmaceuticals stock: price history
1D
-7.0%
1W
-7.6%
1M
-13.0%
6M
-21.3%
YTD
+29.7%
1Y
+47.5%
2Y
+31.2%
5Y
-88.2%
10Y
–
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~2% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vsqueeze-release-v1.0 on 14/10/26. Not a buy or sell signal.Beta
What does this mean?
Volatility squeeze
BearishPrice swings had compressed unusually tight beforehand (volatility near a low) and are now releasing into a stronger move. Technical analysis views such tight phases as often preceding a bigger move.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Atea Pharmaceuticals
Analyst assessment of Atea Pharmaceuticals
PRICE TARGET LOW
US$7.00
CONSENSUS
US$7.00
MEDIAN
US$7.00
PRICE TARGET HIGH
US$7.00
0
STRONG BUY
1
BUY
2
HOLD
1
SELL
0
STRONG SELL
4
TOTAL · Hold
As of: 13/08/2026
Atea Pharmaceuticals stock metrics
P/E
-2.23
P/B
1.82
EV/EBITDA
-1.72
RETURN ON EQUITY
-16.1%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
75.0%
FLOAT SHARES
60,052,335
AVG. DAILY VOLUME (30D)
295,052
Insider transactions (SEC)
Murphy Polly A.
Polsky Bruce
Adams Jerome M.
DUNCAN BARBARA GAYLE
BERGER FRANKLIN M
Institutional holders
Comparable stocks
Frequently asked questions about Atea Pharmaceuticals stock
What does Atea Pharmaceuticals do?
Atea Pharmaceuticals, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Jean-Pierre Sommadossi, the company employs around 55 people.
The IPO was on 30/10/2020; the stock trades on NASDAQ under the ticker AVIR.
What do analysts say about Atea Pharmaceuticals stock?
4 analysts rate the stock, the consensus is Hold (as of 13/08/2026).
The average price target is US$7.00, ranging from US$7.00 to US$7.00, with a median of US$7.00.
This is an external assessment, not a statement by Market Jury.
When does Atea Pharmaceuticals report next?
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly 2% stronger than usual.
Does Atea Pharmaceuticals pay a dividend?
No, Atea Pharmaceuticals currently does not pay a dividend.
Which stocks are comparable to Atea Pharmaceuticals?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Atea Pharmaceuticals stock analyzed?
Clicking "Analyze stock" lets five strategies assess Atea Pharmaceuticals against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.